Invention Grant
- Patent Title: Photoactivatable compositions and to methods for the diagnosis and treating medical conditions
- Patent Title (中): 与用于进行PDT的DNA形成和加合的组合物
-
Application No.: US801831Application Date: 1997-02-14
-
Publication No.: US5773609APublication Date: 1998-06-30
- Inventor: Byron Robinson , Alan R. Morgan , Hugh L. Narciso, Jr.
- Applicant: Byron Robinson , Alan R. Morgan , Hugh L. Narciso, Jr.
- Applicant Address: CA Santa Barbara
- Assignee: PDT Pharmaceuticals, Inc.
- Current Assignee: PDT Pharmaceuticals, Inc.
- Current Assignee Address: CA Santa Barbara
- Main IPC: A61K31/366
- IPC: A61K31/366 ; A61K31/407 ; A61K31/409 ; A61K31/4375 ; A61K41/00 ; A61P9/10 ; A61P17/06 ; A61P27/06 ; A61P35/00 ; C07D487/22 ; C07D493/04 ; C07D519/00 ; A61K31/35
Abstract:
A broad class of photosensitive compounds having enhanced in vivo target tissue selectivity and versatility in photodynamic therapy. Many furocoumarin compounds, such as psoralens, exhibit cytostatic activity when photoactivated but exhibit little in vivo specificity for selectively accumulating in any particular target tissue such as atheromatous plaques. Reactive Oxygen Producing Photosensitizers ("ROPPs") are photoactivatable compounds having an affinity for hyperproliferating cells (such as atheromatous plaque cells), which when photoactivated, produce cytotoxic reaction products. The photoactivity of a ROPP, such as a porphyrin, may be reduced by metalating the porphyrin while the selective affinity of the metalized ROPP for hyperproliferating tissue remains substantially unchanged. By linking a furocoumarin compound to a ROPP to form a F-ROPP, the cytostatic properties of the furocoumarin portion of the F-ROPP can be exploited while the selective affinity of the ROPP portion of the compound for hyperproliferating cells such as atheromatous plaque provides enhanced tissue selectivity without cytotoxicity. In vivo, certain F-ROPPs may be forced to selectively accumulate in a target tissue by illuminating only the target tissue with light having a wavelength operable for photoactivating the F portion of the F-ROPP thereby causing the F-ROPP to either form a monoadduct with or crosslink the cellular DNA in the target tissue. Light of a second wavelength can then be delivered to the target tissue to photoactivate the ROPP portion causing further interference with cellular activity.
Public/Granted literature
- USD338478S Spectacles Public/Granted day:1993-08-17
Information query